Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel Consensus Statement.

Rehm, J. & Shield, K. D. Global Burden of Alcohol Use Disorders and Alcohol Liver Disease. MDPI https://www.mdpi.com/2227-9059/7/4/99 (2019).

Chen, C. M. & Yoon, Y.-H. Surveillance Report #118 Liver Cirrhosis Mortality in the United States: National, State, and Regional Trends, 2000–2019. NIH https://www.niaaa.nih.gov/publications/surveillance-reports/surveillance118#:~:Text=Cirrhosis%20Mortality%20Trends,12.2%20deaths%20per%20100%2C000%20population (2022).

National Institute on Alcohol Abuse and Alcoholism. a. What is Heavy Drinking? NIH https://www.niaaa.nih.gov/health-professionals-communities/core-resource-on-alcohol/basics-defining-how-much-alcohol-too-much#pub-toc4 (2023).

World Health Organization. International Guide for Monitoring Alcohol Consumption and Related Harm (World Health Organization, 2000).

DiMartini, A., Weinrieb, R., Lane, T., Day, N. & Fung, J. Defining the alcoholic liver transplant population: implications for future research. Liver Transpl. 7, 428–431 (2001).

pubmed: 11349263 doi: 10.1053/jlts.2001.23915

Dawson, D. A., Li, T. K. & Grant, B. F. A prospective study of risk drinking: at risk for what? Drug Alcohol Depend. 95, 62–72 (2008).

pubmed: 18243584 pmcid: 2366117 doi: 10.1016/j.drugalcdep.2007.12.007

Singal, A. K., Leggio, L. & DiMartini, A. Alcohol use disorder in alcohol-associated liver disease: two sides of the same coin. Liver Transpl. 30, 200–212 (2023).

pubmed: 37934047 doi: 10.1097/LVT.0000000000000296

Louvet, A. et al. Low alcohol consumption influences outcomes in individuals with alcohol-related compensated cirrhosis in a French multicenter cohort. J. Hepatol. 78, 501–512 (2023).

pubmed: 36423805 doi: 10.1016/j.jhep.2022.11.013

Hofer, B. S. et al. Alcohol abstinence improves prognosis across all stages of portal hypertension in alcohol-related cirrhosis. Clin. Gastroenterol. Hepatol. 21, 2308–2317.e7 (2023).

pubmed: 36481475 doi: 10.1016/j.cgh.2022.11.033

Lackner, C. et al. Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease. J. Hepatol. 66, 610–618 (2017).

pubmed: 27894795 doi: 10.1016/j.jhep.2016.11.011

Mellinger, J., Winder, G. S. & Fernandez, A. C. Measuring the alcohol in alcohol-associated liver disease: choices and challenges for clinical research. Hepatology 73, 1207–1212 (2021).

pubmed: 32886409 doi: 10.1002/hep.31539

Singal, A. K. et al. Research methodologies to address clinical unmet needs and challenges in alcohol-associated liver disease. Hepatology 75, 1026–1037 (2022).

pubmed: 34496071 doi: 10.1002/hep.32143

Institute of Medicine (US) Committee to Improve the National Institutes of Health Consensus Development Program. Consensus Development at the NIH: Improving the Program 1st edn (National Academies Press, 1990).

Bellentani, S. et al. Drinking habits as cofactors of risk for alcohol induced liver damage. the Dionysos Study Group. Gut 41, 845–850 (1997).

pubmed: 9462221 pmcid: 1891602 doi: 10.1136/gut.41.6.845

Knox, J. et al. Reduction in nonabstinent WHO drinking risk levels and change in risk for liver disease and positive AUDIT-C scores: prospective 3-year follow-up results in the U.S. general population. Alcohol Clin. Exp. Res. 42, 2256–2265 (2018).

pubmed: 30204248 pmcid: 6263142 doi: 10.1111/acer.13884

Witkiewitz, K. et al. Drinking risk level reductions associated with improvements in physical health and quality of life among individuals with alcohol use disorder. Alcohol Clin. Exp. Res. 42, 2453–2465 (2018).

pubmed: 30395350 pmcid: 6286196 doi: 10.1111/acer.13897

American Psychiatric Association. Diagnostic and Statistical Manual for Mental Disorders 5th edn (American Psychiatric Publishing, 2013).

World Health Organization. International Classification of Diseases 11th edn (World Health Organization, 2019).

Hasin, D. S. et al. DSM-5 criteria for substance use disorders: recommendations and rationale. Am. J. Psychiatry 170, 834–851 (2013).

pubmed: 23903334 pmcid: 3767415 doi: 10.1176/appi.ajp.2013.12060782

Lundin, A. et al. Towards ICD-11 for alcohol dependence: diagnostic agreement with ICD-10, DSM-5, DSM-IV, DSM-III-R and DSM-III diagnoses in a Swedish general population of women. Drug Alcohol Depend. 227, 108925 (2021).

pubmed: 34358771 doi: 10.1016/j.drugalcdep.2021.108925

Slade, T. et al. DSM-5 and ICD-11 alcohol use disorder criteria in young adult regular drinkers: lifetime prevalence and age of onset. Drug Alcohol Depend. 229, 109184 (2021).

pubmed: 34813987 doi: 10.1016/j.drugalcdep.2021.109184

Scherrer, B. et al. Baseline severity and the prediction of placebo response in clinical trials for alcohol dependence: a meta-regression analysis to develop an enrichment strategy. Alcohol Clin. Exp. Res. 45, 1722–1734 (2021).

pubmed: 34418121 pmcid: 9291112 doi: 10.1111/acer.14670

Aberg, F. et al. Combined effects of alcohol and metabolic disorders in patients with chronic liver disease. Clin. Gastroenterol. Hepatol. 18, 995–997.e2 (2020).

pubmed: 31255807 doi: 10.1016/j.cgh.2019.06.036

Aberg, F., Byrne, C. D., Pirola, C. J., Mannisto, V. & Sookoian, S. Alcohol consumption and metabolic syndrome: clinical and epidemiological impact on liver disease. J. Hepatol. 78, 191–206 (2023).

pubmed: 36063967 doi: 10.1016/j.jhep.2022.08.030

Israelsen, M. et al. Metabolic and genetic risk factors are the strongest predictors of severity of alcohol-related liver fibrosis. Clin. Gastroenterol. Hepatol. 20, 1784–1794.e9 (2022).

pubmed: 33279778 doi: 10.1016/j.cgh.2020.11.038

Rinella, M. E. et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 78, 1966–1986 (2023).

pubmed: 37363821 doi: 10.1097/HEP.0000000000000520

Chalasani, N. et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55, 2005–2023 (2012).

pubmed: 22488764 doi: 10.1002/hep.25762

Chalasani, N. et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67, 328–357 (2018).

pubmed: 28714183 doi: 10.1002/hep.29367

Rehm, J. et al. Alcohol as a risk factor for liver cirrhosis: a systematic review and meta-analysis. Drug Alcohol Rev. 29, 437–445 (2010).

pubmed: 20636661 doi: 10.1111/j.1465-3362.2009.00153.x

Lee, B. P., Dodge, J. L. & Terrault, N. A. National prevalence estimates for steatotic liver disease and sub-classifications using consensus nomenclature. Hepatology 79, 666–673 (2023).

pubmed: 37732946 doi: 10.1097/HEP.0000000000000604

Crabb, D. W., Im, G. Y., Szabo, G., Mellinger, J. L. & Lucey, M. R. Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases. Hepatology 71, 306–333 (2020).

pubmed: 31314133 doi: 10.1002/hep.30866

Thiele, M. et al. Transient and 2-dimensional shear-wave elastography provide comparable assessment of alcoholic liver fibrosis and cirrhosis. Gastroenterology 150, 123–133 (2016).

pubmed: 26435270 doi: 10.1053/j.gastro.2015.09.040

Nguyen-Khac, E. et al. Non-invasive diagnosis of liver fibrosis in patients with alcohol-related liver disease by transient elastography: an individual patient data meta-analysis. Lancet Gastroenterol. Hepatol. 3, 614–625 (2018).

pubmed: 29983372 doi: 10.1016/S2468-1253(18)30124-9

Pavlov, C. S. et al. Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease. Cochrane Database Syst. Rev. 1, CD010542 (2015).

pubmed: 25612182

Trabut, J. B. et al. Rapid decline of liver stiffness following alcohol withdrawal in heavy drinkers. Alcohol Clin. Exp. Res. 36, 1407–1411 (2012).

pubmed: 22404692 doi: 10.1111/j.1530-0277.2012.01737.x

de Franchis, R. et al. Baveno VII — renewing consensus in portal hypertension. J. Hepatol. 76, 959–974 (2022).

pubmed: 35120736 doi: 10.1016/j.jhep.2021.12.022

de Franchis, R. & Baveno, V. I. F. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J. Hepatol. 63, 743–752 (2015).

pubmed: 26047908 doi: 10.1016/j.jhep.2015.05.022

Thiele, M. et al. Accuracy of the enhanced liver fibrosis test vs fibrotest, elastography, and indirect markers in detection of advanced fibrosis in patients with alcoholic liver disease. Gastroenterology 154, 1369–1379 (2018).

pubmed: 29317276 doi: 10.1053/j.gastro.2018.01.005

Papatheodoridi, M. et al. Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease. J. Hepatol. 74, 1109–1116 (2021).

pubmed: 33307138 doi: 10.1016/j.jhep.2020.11.050

Crabb, D. W. et al. Standard definitions and common data elements for clinical trials in patients with alcoholic hepatitis: recommendation from the NIAAA alcoholic hepatitis consortia. Gastroenterology 150, 785–790 (2016).

pubmed: 26921783 doi: 10.1053/j.gastro.2016.02.042

Kilian, C. et al. Stigmatization of people with alcohol use disorders: an updated systematic review of population studies. Alcohol Clin. Exp. Res. 45, 899–911 (2021).

pubmed: 33970504 doi: 10.1111/acer.14598

Schomerus, G. et al. The stigma of alcohol-related liver disease and its impact on healthcare. J. Hepatol. 77, 516–524 (2022).

pubmed: 35526787 doi: 10.1016/j.jhep.2022.04.026

Ashford, R. D., Brown, A. M. & Curtis, B. Substance use, recovery, and linguistics: the impact of word choice on explicit and implicit bias. Drug Alcohol Depend. 189, 131–138 (2018).

pubmed: 29913324 pmcid: 6330014 doi: 10.1016/j.drugalcdep.2018.05.005

Grant, B. F. et al. Epidemiology of DSM-5 alcohol use disorder: results from the National Epidemiologic Survey on alcohol and related conditions III. JAMA Psychiatry 72, 757–766 (2015).

pubmed: 26039070 pmcid: 5240584 doi: 10.1001/jamapsychiatry.2015.0584

DiMartini, A. F., Leggio, L. & Singal, A. K. Barriers to the management of alcohol use disorder and alcohol-associated liver disease: strategies to implement integrated care models. Lancet Gastroenterol. Hepatol. 7, 186–195 (2022).

pubmed: 35026172 doi: 10.1016/S2468-1253(21)00191-6

Link, B. G. & Phelan, J. C. Conceptualizing stigma. Annu. Rev. Sociol. 27, 363–385 (2001).

doi: 10.1146/annurev.soc.27.1.363

Stangl, A. L. et al. The Health Stigma and Discrimination Framework: a global, crosscutting framework to inform research, intervention development, and policy on health-related stigmas. BMC Med. 17, 31 (2019).

pubmed: 30764826 pmcid: 6376797 doi: 10.1186/s12916-019-1271-3

Smith, L. R., Earnshaw, V. A., Copenhaver, M. M. & Cunningham, C. O. Substance use stigma: reliability and validity of a theory-based scale for substance-using populations. Drug Alcohol Depend. 162, 34–43 (2016).

pubmed: 26972790 pmcid: 5293183 doi: 10.1016/j.drugalcdep.2016.02.019

American Association for the Study of Liver Disease, European Association for the Study of the Liver, Latin American Association for the Study of the Liver & Asian Pacific Association for the Study of the Liver. Ending stigmatizing language in alcohol and liver disease: a liver societies’ statement†. Hepatology 78, 1682–1683 (2023).

National Institute on Alcohol Abuse and Alcoholism. Stigma: Overcoming a Pervasive Barrier to Optimum Care. NIH https://www.niaaa.nih.gov/health-professionals-communities/core-resource-on-alcohol/basics-defining-how-much-alcohol-too-much#pub-toc4 (2023).

Zhao, L., Tian, L., Cai, T., Claggett, B. & Wei, L. J. Effectively selecting a target population for a future comparative study. J. Am. Stat. Assoc. 108, 527–539 (2013).

pubmed: 24058223 pmcid: 3775385 doi: 10.1080/01621459.2013.770705

Karriker-Jaffe, K. J., Chartier, K. G., Bares, C. B., Kendler, K. S. & Greenfield, T. K. Intersection of familial risk and environmental social control on high-risk drinking and alcohol dependence in a US national sample of adults. Addict. Behav. 113, 106668 (2021).

pubmed: 33045642 doi: 10.1016/j.addbeh.2020.106668

Kezer, C. A., Simonetto, D. A. & Shah, V. H. Sex differences in alcohol consumption and alcohol-associated liver disease. Mayo Clin. Proc. 96, 1006–1016 (2021).

pubmed: 33714602 doi: 10.1016/j.mayocp.2020.08.020

Vaeth, P. A., Wang-Schweig, M. & Caetano, R. Drinking, alcohol use disorder, and treatment access and utilization among U.S. racial/ethnic groups. Alcohol Clin. Exp. Res. 41, 6–19 (2017).

pubmed: 28019654 doi: 10.1111/acer.13285

Moreno, C., Mueller, S. & Szabo, G. Non-invasive diagnosis and biomarkers in alcohol-related liver disease. J. Hepatol. 70, 273–283 (2019).

pubmed: 30658728 doi: 10.1016/j.jhep.2018.11.025

Witkiewitz, K., Finney, J. W., Harris, A. H., Kivlahan, D. R. & Kranzler, H. R. Recommendations for the design and analysis of treatment trials for alcohol use disorders. Alcohol Clin. Exp. Res. 39, 1557–1570 (2015).

pubmed: 26250333 pmcid: 4558228 doi: 10.1111/acer.12800

Koenig, L. B., Jacob, T. & Haber, J. R. Validity of the lifetime drinking history: a comparison of retrospective and prospective quantity–frequency measures. J. Stud. Alcohol Drugs 70, 296–303 (2009).

pubmed: 19261242 pmcid: 2653615 doi: 10.15288/jsad.2009.70.296

Longnecker, M. P. et al. The reliability of self-reported alcohol consumption in the remote past. Epidemiology 3, 535–539 (1992).

pubmed: 1420522 doi: 10.1097/00001648-199211000-00014

Jayasekara, H. et al. Alcohol consumption for different periods in life, intake pattern over time and all-cause mortality. J. Public Health 37, 625–633 (2015).

Litten, R. Z. & Fertig, J. Self-report and biochemical measures of alcohol consumption. Addiction 98, iii–iv (2003).

pubmed: 14984236 doi: 10.1046/j.1359-6357.2003.00580.x

Litten, R. Z., Bradley, A. M. & Moss, H. B. Alcohol biomarkers in applied settings: recent advances and future research opportunities. Alcohol Clin. Exp. Res. 34, 955–967 (2010).

pubmed: 20374219 doi: 10.1111/j.1530-0277.2010.01170.x

Dettling, A. et al. Ethanol elimination rates in men and women in consideration of the calculated liver weight. Alcohol 41, 415–420 (2007).

pubmed: 17936510 doi: 10.1016/j.alcohol.2007.05.003

Ulwelling, W. & Smith, K. The PEth blood test in the security environment: what it is; why it is important; and interpretative guidelines. J. Forensic Sci. 63, 1634–1640 (2018).

pubmed: 30005144 doi: 10.1111/1556-4029.13874

Helander, A. & Hansson, T. The alcohol biomarker phosphatidylethanol (PEth) — test performance and experiences from routine analysis and external quality assessment. Scand. J. Clin. Lab. Invest. 83, 424–431 (2023).

pubmed: 37697976 doi: 10.1080/00365513.2023.2253734

DiMartini, A. et al. Carbohydrate deficient transferrin in abstaining patients with end-stage liver disease. Alcohol Clin. Exp. Res. 25, 1729–1733 (2001).

pubmed: 11781505 pmcid: 4700931

Morgan, M., Sharma, M. & Atkinson, S. Genetic and environmental susceptibility to alcoholic hepatitis. Clin. Liver Dis. 25, 517–535 (2021).

pubmed: 34229837 doi: 10.1016/j.cld.2021.04.001

Liangpunsakul, S., Haber, P. & McCaughan, G. W. Alcoholic liver disease in Asia, Europe, and North America. Gastroenterology 150, 1786–1797 (2016).

pubmed: 26924091 doi: 10.1053/j.gastro.2016.02.043

Schnabl, B. et al. Liver specific, systemic and genetic contributors to alcohol-related liver disease progression. J. Gastroenterol. 60, 36–44 (2022).

Liangpunsakul, S. et al. Interaction between the patatin-like phospholipase domain-containing protein 3 genotype and coffee drinking and the risk for acute alcoholic hepatitis. Hepatol. Commun. 2, 29–34 (2017).

pubmed: 29404510 pmcid: 5776869 doi: 10.1002/hep4.1123

Ajoolabady, A., Aslkhodapasandhokmabad, H., Zhou, Y. & Ren, J. Epigenetic modification in alcohol-related liver diseases. Med. Res. Rev. 42, 1463–1491 (2022).

pubmed: 35187693 doi: 10.1002/med.21881

Degre, D. et al. Long-term outcomes in patients with decompensated alcohol-related liver disease, steatohepatitis and Maddrey’s discriminant function < 32. J. Hepatol. 72, 636–642 (2020).

pubmed: 31954208 doi: 10.1016/j.jhep.2019.12.023

Moon, A. M., Yang, J. Y., Barritt, A. S. T., Bataller, R. & Peery, A. F. Rising mortality from alcohol-associated liver disease in the United States in the 21st century. Am. J. Gastroenterol. 115, 79–87 (2020).

pubmed: 31688021 doi: 10.14309/ajg.0000000000000442

Israelsen, M. et al. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study. Lancet Gastroenterol. Hepatol. 9, 218–228 (2024).

pubmed: 38218202 doi: 10.1016/S2468-1253(23)00443-0

Dam-Larsen, S. et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 53, 750–755 (2004).

pubmed: 15082596 pmcid: 1774026 doi: 10.1136/gut.2003.019984

Moreau, R. et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 144, 1426–1437.e1–9 (2013).

pubmed: 23474284 doi: 10.1053/j.gastro.2013.02.042

Bajaj, J. S. et al. Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American Consortium for the Study of End-Stage Liver Disease (NACSELD) experience. Hepatology 56, 2328–2335 (2012).

pubmed: 22806618 doi: 10.1002/hep.25947

Vergis, N. et al. In patients with severe alcoholic hepatitis, prednisolone increases susceptibility to infection and infection-related mortality, and is associated with high circulating levels of bacterial DNA. Gastroenterology 152, 1068–1077.e4 (2017).

pubmed: 28043903 doi: 10.1053/j.gastro.2016.12.019

Louvet, A. et al. Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor. Gastroenterology 137, 541–548 (2009).

pubmed: 19445945 doi: 10.1053/j.gastro.2009.04.062

Szabo, G. et al. IL-1 receptor antagonist plus pentoxifylline and zinc for severe alcohol-associated hepatitis. Hepatology 76, 1058–1068 (2022).

pubmed: 35340032 doi: 10.1002/hep.32478

Gawrieh, S. et al. Randomized-controlled trial of anakinra plus zinc vs. prednisone for severe alcohol-associated hepatitis. J. Hepatol. 80, 684–693 (2024).

pubmed: 38342441 doi: 10.1016/j.jhep.2024.01.031

Carlson, R. W. et al. Alcohol withdrawal syndrome. Crit. Care Clin. 28, 549–585 (2012).

pubmed: 22998991 doi: 10.1016/j.ccc.2012.07.004

Rasmussen, D. N. et al. Prognostic performance of 7 biomarkers compared to liver biopsy in early alcohol-related liver disease. J. Hepatol. 75, 1017–1025 (2021).

pubmed: 34118335 pmcid: 8522804 doi: 10.1016/j.jhep.2021.05.037

Labenz, C. et al. Health-related quality of life in patients with compensated and decompensated liver cirrhosis. Eur. J. Intern. Med. 70, 54–59 (2019).

pubmed: 31530418 doi: 10.1016/j.ejim.2019.09.004

Mellinger, J. L. et al. The high burden of alcoholic cirrhosis in privately insured persons in the United States. Hepatology 68, 872–882 (2018).

pubmed: 29579356 doi: 10.1002/hep.29887

Pocock, S., Ariti, C., Collier, T. & Wang, D. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. Eur. Heart J. 33, 176–182 (2012).

pubmed: 21900289 doi: 10.1093/eurheartj/ehr352

Perez, F. et al. Desirability of outcome ranking for the management of antimicrobial therapy (DOOR MAT) reveals improvements in the treatment of bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae in patients from the Veterans Health Administration. Clin. Infect. Dis. 73, 1231–1238 (2021).

pubmed: 33978146 pmcid: 8492112 doi: 10.1093/cid/ciab384

Louvet, A. et al. Main drivers of outcome differ between short term and long term in severe alcoholic hepatitis: a prospective study. Hepatology 66, 1464–1473 (2017).

pubmed: 28459138 doi: 10.1002/hep.29240

Lee, B. P., Vittinghoff, E., Dodge, J. L., Cullaro, G. & Terrault, N. A. National trends and long-term outcomes of liver transplant for alcohol-associated liver disease in the United States. JAMA Intern. Med. 179, 340–348 (2019).

pubmed: 30667468 pmcid: 6439700 doi: 10.1001/jamainternmed.2018.6536

Asrani, S. K. et al. Meeting report: the Dallas Consensus Conference on liver transplantation for alcohol associated hepatitis. Liver Transpl. 26, 127–140 (2020).

pubmed: 31743578 pmcid: 8151800 doi: 10.1002/lt.25681

European Association for the Study of the Liver. EASL clinical practice guidelines: management of alcohol-related liver disease. J. Hepatol. 69, 154–181 (2018).

Arab, J. P. et al. Alcohol-related liver disease: clinical practice guidelines by the Latin American Association for the Study of the Liver (ALEH). Ann. Hepatol. 18, 518–535 (2019).

pubmed: 31053546 doi: 10.1016/j.aohep.2019.04.005

Sobell, L. C. & Sobell, M. B. Measuring Alcohol Consumption: Psychosocial and Biochemical Methods 41–72 (Humana Press/Springer Nature, 1992).

Collins, R. L., Parks, G. A. & Marlatt, G. A. Social determinants of alcohol consumption: the effects of social interaction and model status on the self-administration of alcohol. J. Consult. Clin. Psychol. 53, 189–200 (1985).

pubmed: 3998247 doi: 10.1037/0022-006X.53.2.189

Saunders, J. B., Aasland, O. G., Babor, T. F., de la Fuente, J. R. & Grant, M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption — II. Addiction https://doi.org/10.1111/j.1360-0443.1993.tb02093.x (1993).

Wu, T. et al. Smartphone sensor data estimate alcohol craving in a cohort of patients with alcohol-associated liver disease and alcohol use disorder. Hepatol. Commun. 7, e0329 (2023).

pubmed: 38055637 pmcid: 10984664 doi: 10.1097/HC9.0000000000000329

Pelkonen, O. & Sotaniemi, E. Drug metabolism in alcoholics. Pharmacol. Ther. 16, 261–268 (1982).

pubmed: 6752978 doi: 10.1016/0163-7258(82)90057-2

Moore, A., Whiteman, E. & Ward, K. Risks of combined alcohol/medication use in older adults. Am. J. Geriatr. Pharmacother. 5, 64–74 (2007).

pubmed: 17608249 pmcid: 4063202 doi: 10.1016/j.amjopharm.2007.03.006

Pena, M., Horga, J. & Zapater, P. Variations of pharmacokinetics of drugs in patients with cirrhosis. Expert Rev. Clin. Pharmacol. 9, 441–458 (2016).

pubmed: 26696448 doi: 10.1586/17512433.2016.1135733

Ting, P. S., Wheatley, J. & Chen, P. H. Behavioral treatment for patients with alcohol-related liver disease: a primer for hepatologists. Clin. Liver Dis. 15, 31–35 (2020).

doi: 10.1002/cld.854

Hemrage, S., Brobbin, E., Deluca, P. & Drummond, C. Efficacy of psychosocial interventions to reduce alcohol use in comorbid alcohol use disorder and alcohol-related liver disease: a systematic review of randomized controlled trials. Alcohol Alcohol. 58, 478–484 (2023).

pubmed: 37530582 pmcid: 10493519 doi: 10.1093/alcalc/agad051

DeMartini, K. S. et al. Text messaging to reduce alcohol relapse in prelisting liver transplant candidates: a pilot feasibility study. Alcohol Clin. Exp. Res. 42, 761–769 (2018).

pubmed: 29498753 pmcid: 6438371 doi: 10.1111/acer.13603

Suffoletto, B. & Scaglione, S. Using digital interventions to support individuals with alcohol use disorder and advanced liver disease: a bridge over troubled waters. Alcohol Clin. Exp. Res. 42, 1160–1165 (2018).

pubmed: 29750368 pmcid: 6028285 doi: 10.1111/acer.13771

Magill, M. et al. A meta-analysis of motivational interviewing process: technical, relational, and conditional process models of change. J. Consult. Clin. Psychol. 86, 140–157 (2018).

pubmed: 29265832 doi: 10.1037/ccp0000250

Magill, M. et al. Do what you say and say what you are going to do: a preliminary meta-analysis of client change and sustain talk subtypes in motivational interviewing. Psychother. Res. 29, 860–869 (2018).

pubmed: 29954290 pmcid: 6310665 doi: 10.1080/10503307.2018.1490973

McCrady, B. S., Owens, M. D., Borders, A. Z. & Brovko, J. M. Psychosocial approaches to alcohol use disorders since 1940: a review. J. Stud. Alcohol Drugs Suppl. 75, 68–78 (2014).

pubmed: 24565313 doi: 10.15288/jsads.2014.75.68

Miller, W. R. & Rose, G. S. Toward a theory of motivational interviewing. Am. Psychol. 64, 527–537 (2009).

pubmed: 19739882 pmcid: 2759607 doi: 10.1037/a0016830

Dieperink, E. et al. Efficacy of motivational enhancement therapy on alcohol use disorders in patients with chronic hepatitis C: a randomized controlled trial. Addiction 109, 1869–1877 (2014).

pubmed: 25040898 doi: 10.1111/add.12679

Magill, M. & Ray, L. A. Cognitive-behavioral treatment with adult alcohol and illicit drug users: a meta-analysis of randomized controlled trials. J. Stud. Alcohol Drugs 70, 516–527 (2009).

pubmed: 19515291 pmcid: 2696292 doi: 10.15288/jsad.2009.70.516

Ray, L. A. et al. Combined pharmacotherapy and cognitive behavioral therapy for adults with alcohol or substance use disorders: a systematic review and meta-analysis. JAMA Netw. Open 3, e208279 (2020).

pubmed: 32558914 pmcid: 7305524 doi: 10.1001/jamanetworkopen.2020.8279

Witkiewitz, K., Pfund, R. A. & Tucker, J. A. Mechanisms of behavior change in substance use disorder with and without formal treatment. Annu. Rev. Clin. Psychol. 18, 497–525 (2022).

pubmed: 35138868 doi: 10.1146/annurev-clinpsy-072720-014802

Witkiewitz, K., Litten, R. Z. & Leggio, L. Advances in the science and treatment of alcohol use disorder. Sci. Adv. 5, eaax4043 (2019).

pubmed: 31579824 pmcid: 6760932 doi: 10.1126/sciadv.aax4043

Mann, K., Aubin, H.-J. H.-J. & Witkiewitz, K. Reduced drinking in alcohol dependence treatment, what is the evidence? Eur. Addict. Res. 23, 219–230 (2017).

pubmed: 28934736 doi: 10.1159/000481348

Marlatt, G. A. & Witkiewitz, K. Harm reduction approaches to alcohol use: health promotion, prevention, and treatment. Addict. Behav. 27, 867–886 (2002).

pubmed: 12369473 doi: 10.1016/S0306-4603(02)00294-0

Hallgren, K. A. & Witkiewitz, K. Missing data in alcohol clinical trials: a comparison of methods. Alcohol Clin. Exp. Res. 37, 2152–2160 (2013).

pubmed: 23889334 pmcid: 4113114 doi: 10.1111/acer.12205

Bhatt, D. L. & Mehta, C. Adaptive designs for clinical trials. N. Engl. J. Med. 375, 65–74 (2016).

pubmed: 27406349 doi: 10.1056/NEJMra1510061

Chow, S. C. Adaptive clinical trial design. Annu. Rev. Med. 65, 405–415 (2014).

pubmed: 24422576 doi: 10.1146/annurev-med-092012-112310

Thorlund, K., Haggstrom, J., Park, J. J. & Mills, E. J. Key design considerations for adaptive clinical trials: a primer for clinicians. Br. Med. J. 360, k698 (2018).

doi: 10.1136/bmj.k698

Murphy, S. A. An experimental design for the development of adaptive treatment strategies. Stat. Med. 24, 1455–1481 (2005).

pubmed: 15586395 doi: 10.1002/sim.2022

Sola, E. et al. Endpoints and design of clinical trials in patients with decompensated cirrhosis: position paper of the LiverHope Consortium. J. Hepatol. 74, 200–219 (2021).

pubmed: 32896580 doi: 10.1016/j.jhep.2020.08.009

FDA. Guidance for Industry Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling. FDA https://www.fda.gov/media/71311/download (2003).

Sarin, S. K. et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol. Int. 13, 353–390 (2019).

pubmed: 31172417 doi: 10.1007/s12072-019-09946-3

O’Leary, J. G. et al. NACSELD Acute-on-Chronic Liver Failure (NACSELD-ACLF) score predicts 30-day survival in hospitalized patients with cirrhosis. Hepatology 67, 2367–2374 (2018).

pubmed: 29315693 doi: 10.1002/hep.29773

Singal, A. K. & Mathurin, P. Diagnosis and treatment of alcohol-associated liver disease: a review. JAMA 326, 165–176 (2021).

pubmed: 34255003 doi: 10.1001/jama.2021.7683

Szabo, G., Romics, L. Jr & Frendl, G. Liver in sepsis and systemic inflammatory response syndrome. Clin. Liver Dis. 6, 1045–1066 (2002).

pubmed: 12516206 doi: 10.1016/S1089-3261(02)00058-2

Mookerjee, R. P. et al. The role of liver biopsy in the diagnosis and prognosis of patients with acute deterioration of alcoholic cirrhosis. J. Hepatol. 55, 1103–1111 (2011).

pubmed: 21376092 doi: 10.1016/j.jhep.2011.02.021

Adebayo, D. & Wong, F. Pathophysiology of hepatorenal syndrome — acute kidney injury. Clin. Gastroenterol. Hepatol. 21, S1–S10 (2023).

pubmed: 37625861 doi: 10.1016/j.cgh.2023.04.034

Thursz, M., Kamath, P. S., Mathurin, P., Szabo, G. & Shah, V. H. Alcohol-related liver disease: areas of consensus, unmet needs and opportunities for further study. J. Hepatol. 70, 521–530 (2019).

pubmed: 30658117 doi: 10.1016/j.jhep.2018.10.041

Bataller, R., Arab, J. P. & Shah, V. H. Alcohol-associated hepatitis. N. Engl. J. Med. 387, 2436–2448 (2022).

pubmed: 36577100 doi: 10.1056/NEJMra2207599

Sarin, S. K. et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Hepatol. Int. 3, 269–282 (2009).

pubmed: 19669378 doi: 10.1007/s12072-008-9106-x

Welch, N. et al. Continued muscle loss increases mortality in cirrhosis: impact of aetiology of liver disease. Liver Int. 40, 1178–1188 (2020).

pubmed: 31889396 pmcid: 7195232 doi: 10.1111/liv.14358

Shi, X., DeLucia, A. L., Bao, J. & Zhang, P. Alcohol abuse and disorder of granulopoiesis. Pharmacol. Ther. 198, 206–219 (2019).

pubmed: 30831129 pmcid: 6536325 doi: 10.1016/j.pharmthera.2019.03.001

Silczuk, A. & Habrat, B. Alcohol-induced thrombocytopenia: current review. Alcohol 86, 9–16 (2020).

pubmed: 32330589 doi: 10.1016/j.alcohol.2020.02.166

Simou, E., Britton, J. & Leonardi-Bee, J. Alcohol and the risk of pneumonia: a systematic review and meta-analysis. BMJ Open. 8, e022344 (2018).

pubmed: 30135186 pmcid: 6112384 doi: 10.1136/bmjopen-2018-022344

Sanvisens, A. et al. Folate deficiency in patients seeking treatment of alcohol use disorder. Drug Alcohol Depend. 180, 417–422 (2017).

pubmed: 28988003 doi: 10.1016/j.drugalcdep.2017.08.039

McClain, C. J., Rios, C. D., Condon, S. & Marsano, L. S. Malnutrition and alcohol-associated hepatitis. Clin. Liver Dis. 25, 557–570 (2021).

pubmed: 34229839 pmcid: 8672300 doi: 10.1016/j.cld.2021.03.002

Larsson, S. C., Drca, N. & Wolk, A. Alcohol consumption and risk of atrial fibrillation: a prospective study and dose–response meta-analysis. J. Am. Coll. Cardiol. 64, 281–289 (2014).

pubmed: 25034065 doi: 10.1016/j.jacc.2014.03.048

Taylor, B. et al. Alcohol and hypertension: gender differences in dose–response relationships determined through systematic review and meta-analysis. Addiction 104, 1981–1990 (2009).

pubmed: 19804464 doi: 10.1111/j.1360-0443.2009.02694.x

Manthey, J., Probst, C., Rylett, M. & Rehm, J. National, regional and global mortality due to alcoholic cardiomyopathy in 2015. Heart 104, 1663–1669 (2018).

pubmed: 29535230 doi: 10.1136/heartjnl-2017-312384

Andersson, C., Schou, M., Gustafsson, F. & Torp-Pedersen, C. Alcohol intake in patients with cardiomyopathy and heart failure: consensus and controversy. Circ. Heart Fail. 15, e009459 (2022).

pubmed: 35593142 doi: 10.1161/CIRCHEARTFAILURE.121.009459

Kaul, R. et al. Alcohol and atrial fibrillation: a pathophysiologic perspective. Cardiol. Rev. 31, 177–184 (2023).

pubmed: 36398336 doi: 10.1097/CRD.0000000000000479

Puddey, I. B., Mori, T. A., Barden, A. E. & Beilin, L. J. Alcohol and hypertension — new insights and lingering controversies. Curr. Hypertens. Rep. 21, 79 (2019).

pubmed: 31494743 doi: 10.1007/s11906-019-0984-1

Lankisch, P. G., Apte, M. & Banks, P. A. Acute pancreatitis. Lancet 386, 85–96 (2015).

pubmed: 25616312 doi: 10.1016/S0140-6736(14)60649-8

Vanella, G., Archibugi, L., Stigliano, S. & Capurso, G. Alcohol and gastrointestinal cancers. Curr. Opin. Gastroenterol. 35, 107–113 (2019).

pubmed: 30550381 doi: 10.1097/MOG.0000000000000502

Hammoud, N. & Jimenez-Shahed, J. Chronic neurologic effects of alcohol. Clin. Liver Dis. 23, 141–155 (2019).

pubmed: 30454828 doi: 10.1016/j.cld.2018.09.010

Chalasani, N. et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 135, 1924–1934 (2008).

pubmed: 18955056 doi: 10.1053/j.gastro.2008.09.011

European Association for the Study of the Liver. EASL clinical practice guidelines: drug-induced liver injury. J. Hepatol. 70, 1222–1261 (2019).

doi: 10.1016/j.jhep.2019.02.014

Kamath, P. S. et al. A model to predict survival in patients with end-stage liver disease. Hepatology 33, 464–470 (2001).

pubmed: 11172350 doi: 10.1053/jhep.2001.22172

Jeong, R. et al. Model for end-stage liver disease score as a predictor of short-term outcome in patients with drug-induced liver injury. Scand. J. Gastroenterol. 50, 439–446 (2015).

pubmed: 25639449 doi: 10.3109/00365521.2014.958094

Schmidt, L. E. & Larsen, F. MELD score as a predictor of liver failure and death in patients with acetaminophen-induced liver injury. Hepatology 45, 789–796 (2007).

pubmed: 17326205 doi: 10.1002/hep.21503

Reuben, A., Koch, D. G., Lee, W. & the Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 52, 2065–2076 (2010).

pubmed: 20949552 doi: 10.1002/hep.23937

FDA. Guidance for Industry Drug-Induced Liver Injury: Premarketing Clinical Evaluation. FDA https://www.fda.gov/media/116737/download (2009).

Nadim, M. K. & Garcia-Tsao, G. Acute kidney injury in patients with cirrhosis. N. Engl. J. Med. 388, 733–745 (2023).

pubmed: 36812435 doi: 10.1056/NEJMra2215289

Treem, W. R. et al. Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in adults with chronic viral hepatitis and adults with cirrhosis secondary to hepatitis B, C and nonalcoholic steatohepatitis. Drug Saf. 44, 133–165 (2021).

pubmed: 33141341 doi: 10.1007/s40264-020-01014-2

Coates, S., Taubel, J. & Lorch, U. Practical risk management in early phase clinical trials. Eur. J. Clin. Pharmacol. 75, 483–496 (2019).

pubmed: 30569285 doi: 10.1007/s00228-018-02607-8

Food and Drug Administration. Guidance for industry and investigators safety reporting requirements for INDs and BA/BE studies. FDA https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-reporting-requirements-inds-and-babe-studies (2012).

Walters, S. J. et al. Recruitment and retention of participants in randomised controlled trials: a review of trials funded and published by the United Kingdom health technology assessment programme. BMJ Open 7, e015276 (2017).

pubmed: 28320800 pmcid: 5372123 doi: 10.1136/bmjopen-2016-015276

Fogel, D. B. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review. Contemp. Clin. Trials Commun. 11, 156–164 (2018).

pubmed: 30112460 pmcid: 6092479 doi: 10.1016/j.conctc.2018.08.001

Wong, C. H., Siah, K. W. & Lo, A. W. Estimation of clinical trial success rates and related parameters. Biostatistics 20, 273–286 (2019).

pubmed: 29394327 doi: 10.1093/biostatistics/kxx069

Briel, M. et al. Exploring reasons for recruitment failure in clinical trials: a qualitative study with clinical trial stakeholders in Switzerland, Germany, and Canada. Trials 22, 844 (2021).

pubmed: 34823582 pmcid: 8613940 doi: 10.1186/s13063-021-05818-0

Kasenda, B. et al. Prediction of RECRUITment in randomized clinical trials (RECRUIT-IT) — rationale and design for an international collaborative study. Trials 21, 731 (2020).

pubmed: 32825846 pmcid: 7441612 doi: 10.1186/s13063-020-04666-8

Jacques, R. M. et al. Recruitment, consent and retention of participants in randomised controlled trials: a review of trials published in the National Institute for Health Research (NIHR) Journals Library (1997–2020). BMJ Open 12, e059230 (2022).

pubmed: 35165116 pmcid: 8845327 doi: 10.1136/bmjopen-2021-059230

Natale, P. et al. Transparency, trust and minimizing burden to increase recruitment and retention in trials: a systematic review. J. Clin. Epidemiol. 134, 35–51 (2021).

pubmed: 33515656 doi: 10.1016/j.jclinepi.2021.01.014

Bentley, C. et al. Conducting clinical trials — costs, impacts, and the value of clinical trials networks: a scoping review. Clin. Trials 16, 183–193 (2019).

pubmed: 30628466 doi: 10.1177/1740774518820060

Gul, R. B. & Ali, P. A. Clinical trials: the challenge of recruitment and retention of participants. J. Clin. Nurs. 19, 227–233 (2010).

pubmed: 20500260 doi: 10.1111/j.1365-2702.2009.03041.x

Comerford, M. et al. Challenges in patient enrollment and retention in clinical studies for alcoholic hepatitis: experience of the TREAT consortium. Alcohol Clin. Exp. Res. 41, 2000–2006 (2017).

pubmed: 28981151 pmcid: 5711577 doi: 10.1111/acer.13515

Dasarathy, S. et al. Development and evaluation of objective trial performance metrics for multisite clinical studies: experience from the AlcHep Network. Contemp. Clin. Trials 138, 107437 (2024).

pubmed: 38215876 doi: 10.1016/j.cct.2024.107437

Mellinger, J. L. & Winder, G. S. Alcohol use disorders in alcoholic liver disease. Clin. Liver Dis. 23, 55–69 (2019).

pubmed: 30454833 doi: 10.1016/j.cld.2018.09.004

Winder, G. S., Clifton, E. G., Perumalswami, P. & Mellinger, J. L. The art of interprofessional psychosocial communication: optimizing patient interfaces with psychiatric specialists in liver transplantation. Transpl. Rev. 36, 100728 (2022).

doi: 10.1016/j.trre.2022.100728

Winder, G. S., Fernandez, A. C. & Mellinger, J. L. Integrated care of alcohol-related liver disease. J. Clin. Exp. Hepatol. 12, 1069–1082 (2022).

pubmed: 35814517 pmcid: 9257883 doi: 10.1016/j.jceh.2022.01.010

Kintz, P. Consensus of the society of hair testing on hair testing for chronic excessive alcohol consumption 2011. Forensic Sci. Int. 218, 2 (2012).

pubmed: 22024658 doi: 10.1016/j.forsciint.2011.10.025

Berger, L. et al. Ethyl glucuronide in hair and fingernails as a long-term alcohol biomarker. Addiction 109, 425–431 (2014).

pubmed: 24524319 doi: 10.1111/add.12402

Lees, R. et al. Comparison of ethyl glucuronide in hair with self-reported alcohol consumption. Alcohol Alcohol. 47, 267–272 (2012).

pubmed: 22336766 doi: 10.1093/alcalc/ags010

Vaa, B., Asrani, S., Dunn, W., Kamath, P. & Shah, V. Influence of serum sodium on MELD-based survival prediction in alcoholic hepatitis. Mayo Clin. Proc. 86, 37–42 (2011).

pubmed: 21193654 pmcid: 3012632 doi: 10.4065/mcp.2010.0281

Dunn, W. et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 41, 353–358 (2005).

pubmed: 15660383 doi: 10.1002/hep.20503

Sullivan, J. T., Sykora, K., Schneiderman, J., Naranjo, C. A. & Sellers, E. M. Assessment of alcohol withdrawal: the revised Clinical Institute Withdrawal Assessment for Alcohol Scale (CIWA-Ar). Br. J. Addict. 84, 1353–1357 (1989).

pubmed: 2597811 doi: 10.1111/j.1360-0443.1989.tb00737.x

Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel Consensus Statement.

Journal

Informations de publication

Résumé

Identifiants

Types de publication

Langues

Sous-ensembles de citation

Informations de copyright

Références

Auteurs

Classifications MeSH